Depression Treatment in Six Days: A New Era in Brain Medicine Arrives

NEW YORK, NY – March 13, 2026 – A groundbreaking study published in the peer-reviewed journal Brain Stimulation has confirmed the efficacy of an accelerated protocol that can treat Major Depressive Disorder (MDD) in just six days, a dramatic reduction from the months-long commitment required by traditional therapies. The research, which evaluated BrainsWay's SWIFT™ accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol, signals a potential paradigm shift in how millions of Americans access and experience mental healthcare.

Radial, a company building a national network of advanced psychiatric clinics and a participant in the clinical trial, announced the publication of the two manuscripts, which detail findings from a large, randomized, multisite study. The results demonstrate that the accelerated protocol achieves comparable clinical outcomes to the standard, weeks-long treatment, but in a fraction of the time.

A Paradigm Shift in Treatment Duration

For decades, the logistics of treating severe depression have been a significant hurdle for patients. Standard Transcranial Magnetic Stimulation (TMS) protocols typically require patients to visit a clinic for daily sessions, five days a week, for four to six weeks. This demanding schedule often conflicts with work, family, and other life responsibilities, creating a substantial barrier to starting and completing treatment.

The newly validated SWIFT™ protocol condenses this timeline into an astonishingly brief period. Instead of 36 separate clinic visits, patients undergo a series of sessions over just six half-days. This acute phase is followed by a less intensive maintenance period of weekly visits for four weeks to solidify the gains.

The study's results are not just about convenience; they validate a powerful clinical efficacy. In the randomized non-inferiority trial, patients receiving the accelerated protocol achieved an 87.8% response rate, meaning their depressive symptoms were cut by at least half. Furthermore, an impressive 78.0% of patients achieved full remission, where their symptoms were so minimal they were no longer considered to be clinically depressed. These outcomes were comparable to the standard protocol, proving that speed did not come at the cost of effectiveness. In fact, the median time to remission was even faster for the accelerated group, at 21 days compared to 28 days for the standard protocol.

The Technology Behind the Breakthrough: Deep TMS

At the heart of this innovation is Deep Transcranial Magnetic Stimulation, a non-invasive treatment that uses magnetic fields to gently stimulate nerve cells in specific areas of the brain associated with depression. Unlike antidepressant medications, which affect the entire body, TMS is a targeted therapy with minimal systemic side effects.

BrainsWay's proprietary Deep TMS technology utilizes a unique, patented H-Coil design, which is housed in a cushioned helmet. This allows the magnetic pulses to reach deeper and broader regions of the brain than traditional TMS systems, potentially enhancing its therapeutic effect. The technology has already established a strong track record, with FDA clearances not only for MDD but also for Obsessive-Compulsive Disorder (OCD) and smoking addiction, making it the only TMS company to have secured three such indications backed by pivotal studies.

The accelerated SWIFT™ protocol, which received its own FDA clearance in late 2025, represents the latest evolution of this platform. By administering multiple sessions per day in a safe and tolerable manner, it maximizes the therapeutic impact in a condensed timeframe.

Overcoming Barriers to Care for Millions

More than 20 million adults in the United States live with Major Depressive Disorder, a condition that can be debilitating for individuals and carries an estimated annual economic burden of $333 billion. For the 20-40% of patients who do not respond to traditional antidepressant medications or psychotherapy, options can feel limited.

This new protocol directly addresses the most common and practical obstacles that prevent people from seeking or completing care. By consolidating the treatment into less than a week, it dramatically reduces the burden of travel, time off from work, and the need for extended childcare.

"This research represents an important step forward in improving access to effective depression treatment," said Radial Chief Medical Officer and Co-founder Dr. Owen Muir in the company's press release. "By significantly reducing the time and travel, and improving time to remission, accelerated protocols like SWIFT may help more patients start and complete safe and effective treatment."

The impact on patients' lives extends beyond clinical symptom ratings. The study also tracked patient-reported outcomes, which showed meaningful improvements in quality of life and daily functioning. Approximately 60% of participants returned to a normal range of functioning after treatment. The proportion of patients experiencing severe impairment in their quality of life plummeted from nearly 100% at the start of the trial to just 15-17% by the end.

Building the Infrastructure for a New Standard of Care

The availability of a revolutionary treatment is only one part of the equation; making it accessible is the next critical challenge. This is the mission of companies like Radial, which is moving beyond research participation to actively build the clinical infrastructure needed to deliver these advanced therapies across the country.

Radial's model focuses on creating a network of clinics specializing in novel psychiatric treatments, including neuromodulation like Deep TMS and interventional medications. The company's stated goal is to develop the necessary infrastructure, reimbursement tools, and decision support systems to make these transformative options a mainstream reality for patients.

Securing insurance coverage is a crucial step in this process. While the SWIFT™ protocol is FDA-cleared, broad adoption hinges on payers updating their reimbursement policies to cover the accelerated schedule. Progress is already being made on this front, with BrainsWay reporting that several insurance providers have begun to cover the protocol. In a promising sign for the industry, major players like Evernorth Behavioral Health have started to eliminate prior authorization requirements for TMS, simplifying the path to care for millions of patients under Cigna Healthcare plans.

As clinics like those in the Radial network begin to offer the six-day protocol, it represents a tangible step toward a future where the most effective treatments for depression are also the most accessible, offering rapid hope to those who need it most.